- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Italy: number of drug treatments for chronic Hepatitis C 2017, by region
Premium statistics
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
Italy: number of drug treatments for chronic Hepatitis C 2017, by region
Number of drug treatments for chronic Hepatitis C in Italy in 2017, by region
by Statista Research Department,
last edited
Aug 24, 2018
This statistic depicts the number of drug treatments for chronic Hepatitis C in Italy in 2017, by region. According to data, most of the drug treatments against chronic Hepatitis C were provided in Lombardy (8,778), Campania (6,094) and Apulia (3,789). Molise and Aosta Valley were the regions with the lowest number of treatments.
Number of drug treatments for chronic Hepatitis C in Italy in 2017, by region
| Number of treatments | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| Number of treatments | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
Exclusive content
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
by Statista Research Department,
last edited
Aug 24, 2018
This statistic depicts the number of drug treatments for chronic Hepatitis C in Italy in 2017, by region. According to data, most of the drug treatments against chronic Hepatitis C were provided in Lombardy (8,778), Campania (6,094) and Apulia (3,789). Molise and Aosta Valley were the regions with the lowest number of treatments.
- Show sources information
- Show publisher information
- Release date
- July 2018
- Region
- Italy
- Survey time period
- 2017
Source
- Show sources information
- Show publisher information
- Release date
- July 2018
More information
- Region
- Italy
- Survey time period
- 2017
Other statistics on the topic
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.Marlene Greenfield
Vice President, Hearst Magazines
Statistics on "Hepatitis in the U.S. "
- Overview
The most important statistics
- Number of new cases of hepatitis A and B in the U.S. from 1970 to 2016New cases of hepatitis in the U.S. 1970-2016
- New cases of hepatitis A and B per 100,000 population in the U.S. from 1970 to 2016New cases of hepatitis A and B 1970-2016
- Number of viral hepatitis-related deaths in the U.S. from 2012 to 2016, by typeNumber of viral hepatitis-related deaths in the U.S. from 2012-2016, by type
- Rate of viral hepatitis-related deaths in the U.S. from 2012 to 2016, by type (per 100,000 population)Rate of viral hepatitis-related deaths in the U.S. from 2012-2016, by type
- Most expensive prescription drugs in the U.S. as of January 2017 (in U.S. dollars)*Most expensive prescription drugs in the U.S. January 2017
- Hepatitis A
The most important statistics
- Number of viral hepatitis A infections in the U.S. from 2012 to 2016 Number of hepatitis A infections in the U.S. from 2012 to 2016
- Rate of viral hepatitis A infections in the U.S. from 2012 to 2016 (per 100,000 population)Rate of hepatitis A infections in the U.S. from 2012 to 2016
- Number of viral hepatitis A infections in the U.S. as of 2016, by state Number of hepatitis A infections in the U.S. in 2016, by state
- Rate of viral hepatitis A infection in the U.S. as of 2016, by state (per 100,000 population)Hepatitis A infection rate in the U.S. in 2016, by state
- Rate of viral hepatitis A-related deaths in the U.S. from 2012 to 2016, by gender (per 100,000 population)Rate of hepatitis A-related deaths in the U.S. from 2012-2016, by gender
- Rate of viral hepatitis A-related deaths in the U.S. in 2016, by age (per 100,000 population)Rate of hepatitis A-related deaths in the U.S. in 2016, by age
- Rate of viral hepatitis A-related deaths in the U.S. in 2016, by ethnicity (per 100,000 population)Rate of hepatitis A-related deaths in the U.S. in 2016, by ethnicity
- Hepatitis B
The most important statistics
- Number of viral hepatitis B infections in the U.S. from 2012 to 2016Number of hepatitis B infections in the U.S. from 2012-2016
- Rate of viral hepatitis B infections in the U.S. from 2012 to 2016 (per 100,000 population)Rate of hepatitis B infections in the U.S. from 2012-2016
- Number of viral hepatitis B infections in the U.S. as of 2016, by state Number of hepatitis B infections in the U.S. in 2016, by state
- Rate of viral hepatitis B infections in the U.S. as of 2016, by state (per 100,000 population)Rate of hepatitis B infections in the U.S. in 2016, by state
- Rate of viral hepatitis B-related deaths in the U.S. from 2012 to 2016, by gender (per 100,000 population)Rate of hepatitis B-related deaths in the U.S. from 2012-2016, by gender
- Rate of viral hepatitis B-related deaths in the U.S. in 2016, by age (per 100,000 population)Rate of hepatitis B-related deaths in the U.S. in 2016, by age
- Rate of viral hepatitis B-related deaths in the U.S. in 2016, by ethnicity (per 100,000 population)Rate of hepatitis B-related deaths in the U.S. in 2016, by ethnicity
- Hepatitis C
The most important statistics
- Number of acute hepatitis C infections in the U.S. from 2012 to 2016 Number of acute hepatitis C infections in the U.S. from 2012 to 2016
- Number of new hepatitis C patients in the United States from 2011 to 2016 (in 1,000)New hepatitis C patients in the U.S. 2011-2016
- Rate of acute hepatitis C infections in the U.S. from 2012 to 2016 (per 100,000 population)Rate of acute hepatitis C infections in the U.S. from 2012 to 2016
- Number of acute hepatitis C infections in the U.S. as of 2016, by state*Number of acute hepatitis C infections in the U.S. in 2016, by state
- Rate of acute hepatitis C infections in the U.S. as of 2016, by state (per 100,000 population)*Rate of acute hepatitis C infections in the U.S. in 2016, by state
- Rate of viral hepatitis C-related deaths in the U.S. from 2012 to 2016, by gender (per 100,000 population)Rate of hepatitis C-related deaths in the U.S. from 2012-2016, by gender
- Rate of hepatitis C-related deaths in the U.S. in 2016, by age (per 100,000 population)Rate of hepatitis C-related deaths in the U.S. in 2016, by age
- Rate of hepatitis C-related deaths in the U.S. in 2016, by ethnicity (per 100,000 population)Rate of hepatitis C-related deaths in the U.S. in 2016, by ethnicity
- Vaccinations
The most important statistics
- Percentage of U.S. children aged 19-35 months who received all doses of recommended vaccines in 2017Share of U.S. children who received all doses of recommended vaccines 2017
- Percentage of adolescents in the U.S. aged 13 to 17 years who had received select vaccinations in 2017 and 2018Share of U.S. teenagers who had select vaccinations 2017-2018
- Percentage of U.S. adolescents aged 13 to 17 years who had received select vaccinations as of 2017, by poverty levelShare of U.S. teenagers who had select vaccinations 2017, by poverty level
- Percentage of adults diagnosed with diabetes who had the 3-dose hepatitis B vaccination schedule in the U.S. as of 2015, by genderDiabetic adults who had the 3-dose vaccination for hepatitis B U.S. 2015, by age
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Italy: number of drug treatments in 2016, by ATC
- Italy: consumption of cancer drugs 2017, by region
- Italy: consumption rate of drugs to treat hypertension 2017, by category
- Italy: number of therapies undertaken to teat hepatitis C 2015-2017
- Italy: consumption of drugs belonging to category A 2017, by region
- Treatment of chronic diseases of Chinese high-net-worth individuals 2014, by facility
- Treatment for complex chronic diseases of Chinese high-net-worth individuals 2014
- Distribution of heroin users entering drug treatment in Denmark 2017, by gender
- Opinion: access to treatment for patients with life threatening illnesses UK 2016
- Distribution of cocaine users entering drug treatment in Sweden 2017, by gender
- Adults in select countries worldwide who had long-standing health conditions 2018
Studies
- U.S. pharmaceutical industry
- Oncology
- Personalized medicine
- Antibiotic use in Italy
- Drug use in the Nordic countries
- Drug use in Denmark
- Recent Trends in Hospital Drug Spending and Manufacturer Shortages (2019)
- Eli Lilly and Company - 2018 Form 10-K
- The State of Innovation in Highly Prevalent Chronic Diseases 2019
- Assessing Canada’s Drug Shortage Problem
- Report to Congressional Addressees - Drug Shortages (February 2014)
Statistics on "Hepatitis in the U.S. "
- Number of new cases of hepatitis A and B in the U.S. from 1970 to 2016
- New cases of hepatitis A and B per 100,000 population in the U.S. from 1970 to 2016
- Number of viral hepatitis-related deaths in the U.S. from 2012 to 2016, by type
- Rate of viral hepatitis-related deaths in the U.S. from 2012 to 2016, by type (per 100,000 population)
- Most expensive prescription drugs in the U.S. as of January 2017 (in U.S. dollars)*
- Number of viral hepatitis A infections in the U.S. from 2012 to 2016
- Rate of viral hepatitis A infections in the U.S. from 2012 to 2016 (per 100,000 population)
- Number of viral hepatitis A infections in the U.S. as of 2016, by state
- Rate of viral hepatitis A infection in the U.S. as of 2016, by state (per 100,000 population)
- Rate of viral hepatitis A-related deaths in the U.S. from 2012 to 2016, by gender (per 100,000 population)
- Rate of viral hepatitis A-related deaths in the U.S. in 2016, by age (per 100,000 population)
- Rate of viral hepatitis A-related deaths in the U.S. in 2016, by ethnicity (per 100,000 population)
- Number of viral hepatitis B infections in the U.S. from 2012 to 2016
- Rate of viral hepatitis B infections in the U.S. from 2012 to 2016 (per 100,000 population)
- Number of viral hepatitis B infections in the U.S. as of 2016, by state
- Rate of viral hepatitis B infections in the U.S. as of 2016, by state (per 100,000 population)
- Rate of viral hepatitis B-related deaths in the U.S. from 2012 to 2016, by gender (per 100,000 population)
- Rate of viral hepatitis B-related deaths in the U.S. in 2016, by age (per 100,000 population)
- Rate of viral hepatitis B-related deaths in the U.S. in 2016, by ethnicity (per 100,000 population)
- Number of acute hepatitis C infections in the U.S. from 2012 to 2016
- Number of new hepatitis C patients in the United States from 2011 to 2016 (in 1,000)
- Rate of acute hepatitis C infections in the U.S. from 2012 to 2016 (per 100,000 population)
- Number of acute hepatitis C infections in the U.S. as of 2016, by state*
- Rate of acute hepatitis C infections in the U.S. as of 2016, by state (per 100,000 population)*
- Rate of viral hepatitis C-related deaths in the U.S. from 2012 to 2016, by gender (per 100,000 population)
- Rate of hepatitis C-related deaths in the U.S. in 2016, by age (per 100,000 population)
- Rate of hepatitis C-related deaths in the U.S. in 2016, by ethnicity (per 100,000 population)
- Projected reductions in hepatitis C-related complications due to new treatments in the U.S. by 2050
- Cure rates of hepatitis C in the U.S. between 2001 and 2016, by generation treatment type
- Number of inpatient stays involving hepatitis C among U.S. adults in 2005 and 2014
- Distribution of leading co-occurring diagnoses of inpatient stays involving hepatitis C among U.S. adults in 2014
- Distribution of leading comorbidities of inpatient stays involving hepatitis C among U.S. adults in 2014
- Percentage of U.S. children aged 19-35 months who received all doses of recommended vaccines in 2017
- Percentage of adolescents in the U.S. aged 13 to 17 years who had received select vaccinations in 2017 and 2018
- Percentage of U.S. adolescents aged 13 to 17 years who had received select vaccinations as of 2017, by poverty level
- Percentage of adults diagnosed with diabetes who had the 3-dose hepatitis B vaccination schedule in the U.S. as of 2015, by gender
- Number of drug treatments in Italy in 2016, by Anatomical Therapeutic Chemical Classification System (ATC)
- Level of consumption of cancer drugs in Italy in 2017, by region (in DDD* per 1,000 inhabitants per day)
- Level of consumption of drugs to treat hypertension and cardiac decompensation in Italy in 2017, by category (in DDD* per 1,000 inhabitants per day)
- Number of therapies undertaken to treat hepatitis C in Italy from 2015 to 2017
- Consumption of drugs belonging to category A* in Italy from January to October 2017, by region (in DDD**)
- Breakdown of chronic disease treatment among Chinese high-net-worth individuals as of 2014, by facility
- Breakdown of complex chronic disease treatment among Chinese high-net-worth individuals as of 2014, by facility
- Distribution of heroin users entering specialized drug treatment services in Denmark in 2017, by gender
- Thinking about access to treatment for patients with life threatening illnesses, to what extent do you agree or disagree with the following statements?
- Distribution of cocaine users entering specialized drug treatment services in Sweden in 2017, by gender
- Percentage of adults in select countries worldwide who stated they had long-standing health conditions as of 2018
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Save statistic in .XLS format
You can only download this statistic as a Premium user.
Save statistic in .PNG format
You can only download this statistic as a Premium user.
Save statistic in .PDF format
You can only download this statistic as a Premium user.
Show source references
As a Premium user you get access to the detailed source references and background information about this statistic.
Show details about this statistic
As a Premium user you get access to background information and details about the release of this statistic.
Bookmark statistics
As soon as this statistic is updated, you will immediately be notified via e-mail.
Change statistics options
You need at least a Premium Account to use this feature.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.